peroxisomal biogenesis disorders

peroxisomal biogenesis disorders
Name	Peroxisomal biogenesis disorders
Synonyms	Zellweger spectrum disorders, Zellweger syndrome, Neonatal adrenoleukodystrophy, Infantile Refsum disease
Field	Medical genetics, Biochemistry
Onset	Neonatal to childhood
Causes	Mutations in PEX genes
Diagnosis	Biochemical testing, genetic testing, Newborn screening
Treatment	Supportive care, experimental therapies

peroxisomal biogenesis disorders are a group of inherited metabolic conditions caused by defects in peroxisome assembly and function first characterized in the late 20th century. They produce multisystem disease with neurologic, hepatic, and sensorineural involvement and have informed broader studies in cell biology, genetics and molecular biology. Research into these disorders connects to institutions and investigators associated with major advances in rare disease genomics and metabolic medicine.

Overview

Peroxisomal biogenesis disorders encompass a clinically and genetically heterogeneous set of conditions defined by impaired assembly of peroxisomes, organelles critical for lipid metabolism and reactive oxygen species handling. Foundational work by investigators at centers like Massachusetts Institute of Technology, Harvard Medical School, Johns Hopkins University, University of Cambridge and laboratories influenced by laureates such as Paul Nurse, Sydney Brenner, Harvey Cushing helped establish key assays and models. The disorders include severe neonatal phenotypes and milder childhood presentations and intersect with research themes pursued at institutions including National Institutes of Health, Wellcome Trust, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory and patient advocacy groups such as March of Dimes.

Genetics and Molecular Pathogenesis

Peroxisomal biogenesis depends on peroxin proteins encoded by PEX genes; pathogenic variants in genes like PEX1, PEX2, PEX3, PEX5, PEX6 and PEX10 disrupt import of matrix proteins and membrane assembly. The genetics were elucidated through collaborations among researchers at centers including Stanford University, University of California, San Francisco, University of Oxford, Karolinska Institute and consortia funded by agencies like European Commission and National Science Foundation. Molecular studies using model organisms from Saccharomyces cerevisiae to Danio rerio and mammalian systems at institutes such as Max Planck Society and Salk Institute demonstrated mechanisms including defective peroxisomal protein targeting signals, ubiquitination, AAA ATPase dysfunction and impaired β-oxidation of very-long-chain fatty acids. These pathways interface with pathways studied by groups associated with awards such as the Lasker Award and the Nobel Prize in disciplines overlapping cell trafficking and organelle biogenesis.

Clinical Presentation and Subtypes

Clinical subtypes range from the classical neonatal Zellweger syndrome phenotype to neonatal adrenoleukodystrophy and infantile Refsum disease; severity correlates with residual peroxisome function. Infants with severe forms show hypotonia, craniofacial dysmorphism, hepatomegaly and seizures, while milder forms present with progressive neuropathy, vision and hearing loss, and adrenal insufficiency. Phenotypic descriptions were refined in clinical series published by pediatric centers such as Children's Hospital of Philadelphia, Great Ormond Street Hospital, Boston Children's Hospital and influenced diagnostic criteria used in regional programs like Newborn screening initiatives in countries represented by United States Department of Health and Human Services, NHS England and health agencies in Japan, Canada and Australia. Multisystem involvement implicates specialists from neurology clinics at Mayo Clinic, metabolic teams at Cleveland Clinic and endocrine services associated with academic hospitals such as Massachusetts General Hospital.

Diagnosis and Laboratory Evaluation

Diagnosis integrates biochemical screening for elevated very-long-chain fatty acids, phytanic acid, bile acid intermediates and plasmalogen deficiency with molecular genetic testing of PEX genes conducted in clinical laboratories affiliated with centers like Mayo Clinic Laboratories, Quest Diagnostics, and academic core facilities at Broad Institute. Imaging using MRI performed at centers such as Johns Hopkins Hospital and neurophysiology evaluations at institutions like University College London Hospitals assist phenotype delineation. Newborn screening programs and genomic sequencing initiatives coordinated by organizations including Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control and regional newborn screening consortia have improved early detection, while reference standards and variant curation align with guidance from bodies like the American College of Medical Genetics and Genomics.

Management and Treatment

There is no curative standard therapy; management is multidisciplinary with supportive care from neurologists, hepatologists, endocrinologists and rehabilitation teams at tertiary centers such as Texas Children's Hospital and Robert Wood Johnson University Hospital. Experimental approaches include allogeneic hematopoietic stem cell transplantation explored in collaborations involving transplant centers like Fred Hutchinson Cancer Center and gene therapy efforts developed in partnership between academic groups and biotechnology companies in hubs such as Silicon Valley and Boston. Trials and compassionate-use programs have been conducted under regulatory frameworks of agencies including the Food and Drug Administration and European Medicines Agency, with outcomes monitored via registries supported by nonprofits such as National Organization for Rare Disorders and European patient networks. Symptomatic treatments address seizures, nutritional support, adrenal replacement, and vision/hearing rehabilitation provided by clinics affiliated with Johns Hopkins School of Medicine and other tertiary centers.

Epidemiology and Prognosis

Peroxisomal biogenesis disorders are rare; incidence estimates vary by population with higher prevalence reported in founder populations studied by researchers at institutions like McGill University and University of Toronto and registries coordinated by national agencies in Netherlands, Norway and Iceland. Prognosis depends on subtype and residual peroxisomal function: classical neonatal forms often result in early mortality, whereas milder phenotypes permit survival into childhood or adulthood with progressive disability. Longitudinal natural history studies have been undertaken by consortia and academic networks funded by organizations such as Wellcome Trust, Howard Hughes Medical Institute and national health research councils to inform counseling, policy, and therapeutic development.

Category:Genetic disorders